Following the sell-off, Lilly trades at a forward price-to-earnings (P/E) of 37 times 2025 analyst estimates, with a price-to ...

CompanyOverview|NYSE:LLY] The world’s largest pharmaceutical stock, Eli Lilly and Company (NYSE: LLY), recently had its worst ...

Eli Lilly (LLY) has recently been on Zacks.com's list of the most searched stocks. Therefore, you might want to consider some ...

Eli Lilly on Thursday posted better-than-expected quarterly results, but CVS Health's decision to drop the company's obesity ...

In this article, we are going to take a look at where Eli Lilly and Compnay (NYSE ... However, Cramer noted that the company then revealed plans to build $500 billion worth of AI infrastructure ...

Eli Lilly and Company (NYSE:LLY) will participate in the Bank of America Securities 2025 Healthcare Conference, May 15, 2025. Lucas Montarce, Lilly executive vice president and chief financial ...

Eli Lilly and Company (LLY) reported its first-quarter results for 2025, revealing a revenue increase of 45% compared to the same period last year, driven by strong sales of key products.

Wegovy and Zepbound are part of a wave of obesity medications known as GLP-1 receptor agonists that have soared in popularity ...

Jim Cramer’s love for Eli Lilly and Company (NYSE:LLY) has been justified, with the stock being up 20.08% over the past 12 months. Jim Cramer remains a fan and continues to own the stock.

Eli Lilly (LLY) stock dips as CVS Health (CVS) limits access to its weight loss drug Zepbound in favor of Novo Nordisk's (NVO ...

In this article, we are going to take a look at where Eli Lilly and Compnay (NYSE ... However, Cramer noted that the company then revealed plans to build $500 billion worth of AI infrastructure in the ...

Eli Lilly and Company (NYSE:LLY) reported explosive revenue growth in its Q1 2025 earnings presentation on May 1, driven by continued strong performance of its GLP-1 receptor agonists for diabetes and ...